国际医药卫生导报2009，Vol.15Issue(1)：66-69,4.DOI:10.3760/cma.J.issn.1007-1245.2009.01.027
吉西他滨联合卡铂一线治疗老年非小细胞肺癌的临床研究
Clinical observation of gemcitabine plus carboplatin in the treatment of elder non-small call lung cancer
金川 1马磊 1张永晖 1陈文晟 1刘晓燕 1李卫东 1吴迪1
作者信息
- 1. 510095,广州医学院附属肿瘤医院内科
- 折叠
摘要
Abstract
Objective To evaluate the curative effect and toxicity of Gemcitabine plus Carboplatin in the treatment of elder Non-Small Cell Lung Cancer. Methods sixty five elder Non-Small Cell Lung Cancer were enrolled into this study. Gemcitabine 1000 mg/m2 i. v Results It shows that CR 3.1%, PR 43.1%,NC 32.3%, PD 21.5%. The median time to progress and median survival time was 6.5 and 9.3 months, the one year survival rate was 43.1%. The main side effect include Ⅲ～Ⅳ grade leukopenia 27.7%, Ⅲ grade thombocytopenia 4.6%. Conclu-sion Gemcitabine plus Carboplatin is effective for elder Non-Small Cell Lung Cancer and well tolerated.关键词
非小细胞肺癌/药物疗法/联合用药/吉西他滨/卡铂Key words
Non-Small Cell Lung Cancer/Drug therapy/Combined therapy/Gemcitabine分类
医药卫生引用本文复制引用
金川,马磊,张永晖,陈文晟,刘晓燕,李卫东,吴迪..吉西他滨联合卡铂一线治疗老年非小细胞肺癌的临床研究[J].国际医药卫生导报,2009,15(1):66-69,4.
